<DOC>
	<DOC>NCT02270307</DOC>
	<brief_summary>Evaluating the effectiveness of the new protocol which replace the standard immunosuppressive therapy with use of MSCs and CY in patients at high risk of relapse.</brief_summary>
	<brief_title>MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis</brief_title>
	<detailed_description>This trial try to find a new way of refractory hematological malignancies treatment. Aim of this study evaluating the effectiveness of the new protocol which replace the standard immunosuppressive therapy with use of MSCs and CY in patients at high risk of relapse.</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Refractory forms of acute leukemia, but in complete remission (CR) Second and third remission of acute leukemia 2nd and 3rd chronic phase chronic myelogenous leukemia (CML) (or Ph + ALL) relapsed multiple myeloma advanced leukemia ICU Mechanical ventilation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>